Everolimus-eluting stents or bypass surgery for left main coronary artery disease.
<h4>Background</h4> <p>Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents may be an acceptable alternative to CABG in selected patients with left mai...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2016
|
| _version_ | 1797103595455250432 |
|---|---|
| author | Stone, GW Sabik, JF Serruys, PW Simonton, CA Généreux, P Puskas, J Kandzari, DE Morice, MC Lembo, N Brown, WM Taggart, DP Banning, A Merkely, B Horkay, F Boonstra, PW van Boven, AJ Ungi, I Bogáts, G Mansour, S Noiseux, N Sabaté, M Pomar, J Hickey, M Gershlick, A Buszman, P Bochenek, A Schampaert, E Pagé, P Dressler, O Kosmidou, I Mehran, R Pocock, SJ Kappetein, AP |
| author_facet | Stone, GW Sabik, JF Serruys, PW Simonton, CA Généreux, P Puskas, J Kandzari, DE Morice, MC Lembo, N Brown, WM Taggart, DP Banning, A Merkely, B Horkay, F Boonstra, PW van Boven, AJ Ungi, I Bogáts, G Mansour, S Noiseux, N Sabaté, M Pomar, J Hickey, M Gershlick, A Buszman, P Bochenek, A Schampaert, E Pagé, P Dressler, O Kosmidou, I Mehran, R Pocock, SJ Kappetein, AP |
| author_sort | Stone, GW |
| collection | OXFORD |
| description | <h4>Background</h4> <p>Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents may be an acceptable alternative to CABG in selected patients with left main coronary disease.</p> <h4>Methods</h4> <p>We randomly assigned 1905 eligible patients with left main coronary artery disease of low or intermediate anatomical complexity to undergo either percutaneous coronary intervention (PCI) with fluoropolymer-based cobalt–chromium everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). Anatomic complexity was assessed at the sites and defined by a Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower (the SYNTAX score reflects a comprehensive angiographic assessment of the coronary vasculature, with 0 as the lowest score and higher scores [no upper limit] indicating more complex coronary anatomy). The primary end point was the rate of a composite of death from any cause, stroke, or myocardial infarction at 3 years, and the trial was powered for noninferiority testing of the primary end point (noninferiority margin, 4.2 percentage points). Major secondary end points included the rate of a composite of death from any cause, stroke, or myocardial infarction at 30 days and the rate of a composite of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years. Event rates were based on Kaplan–Meier estimates in time-to-first-event analyses.</p> <h4>Results</h4> <p>At 3 years, a primary end-point event had occurred in 15.4% of the patients in the PCI group and in 14.7% of the patients in the CABG group (difference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 percentage points; P = 0.02 for noninferiority; hazard ratio, 1.00; 95% confidence interval, 0.79 to 1.26; P = 0.98 for superiority). The secondary end-point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9% of the patients in the PCI group and in 7.9% in the CABG group (P<0.001 for noninferiority, P = 0.008 for superiority). The secondary end-point event of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years occurred in 23.1% of the patients in the PCI group and in 19.1% in the CABG group (P = 0.01 for noninferiority, P = 0.10 for superiority).</p> <h4>Conclusions</h4> <p>In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years.</p> |
| first_indexed | 2024-03-07T06:22:17Z |
| format | Journal article |
| id | oxford-uuid:f31a2085-f0ae-4f10-b669-df9319be19b7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:22:17Z |
| publishDate | 2016 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:f31a2085-f0ae-4f10-b669-df9319be19b72022-03-27T12:09:31ZEverolimus-eluting stents or bypass surgery for left main coronary artery disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f31a2085-f0ae-4f10-b669-df9319be19b7EnglishSymplectic Elements at OxfordMassachusetts Medical Society2016Stone, GWSabik, JFSerruys, PWSimonton, CAGénéreux, PPuskas, JKandzari, DEMorice, MCLembo, NBrown, WMTaggart, DPBanning, AMerkely, BHorkay, FBoonstra, PWvan Boven, AJUngi, IBogáts, GMansour, SNoiseux, NSabaté, MPomar, JHickey, MGershlick, ABuszman, PBochenek, ASchampaert, EPagé, PDressler, OKosmidou, IMehran, RPocock, SJKappetein, AP <h4>Background</h4> <p>Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents may be an acceptable alternative to CABG in selected patients with left main coronary disease.</p> <h4>Methods</h4> <p>We randomly assigned 1905 eligible patients with left main coronary artery disease of low or intermediate anatomical complexity to undergo either percutaneous coronary intervention (PCI) with fluoropolymer-based cobalt–chromium everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). Anatomic complexity was assessed at the sites and defined by a Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower (the SYNTAX score reflects a comprehensive angiographic assessment of the coronary vasculature, with 0 as the lowest score and higher scores [no upper limit] indicating more complex coronary anatomy). The primary end point was the rate of a composite of death from any cause, stroke, or myocardial infarction at 3 years, and the trial was powered for noninferiority testing of the primary end point (noninferiority margin, 4.2 percentage points). Major secondary end points included the rate of a composite of death from any cause, stroke, or myocardial infarction at 30 days and the rate of a composite of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years. Event rates were based on Kaplan–Meier estimates in time-to-first-event analyses.</p> <h4>Results</h4> <p>At 3 years, a primary end-point event had occurred in 15.4% of the patients in the PCI group and in 14.7% of the patients in the CABG group (difference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 percentage points; P = 0.02 for noninferiority; hazard ratio, 1.00; 95% confidence interval, 0.79 to 1.26; P = 0.98 for superiority). The secondary end-point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9% of the patients in the PCI group and in 7.9% in the CABG group (P<0.001 for noninferiority, P = 0.008 for superiority). The secondary end-point event of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years occurred in 23.1% of the patients in the PCI group and in 19.1% in the CABG group (P = 0.01 for noninferiority, P = 0.10 for superiority).</p> <h4>Conclusions</h4> <p>In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years.</p> |
| spellingShingle | Stone, GW Sabik, JF Serruys, PW Simonton, CA Généreux, P Puskas, J Kandzari, DE Morice, MC Lembo, N Brown, WM Taggart, DP Banning, A Merkely, B Horkay, F Boonstra, PW van Boven, AJ Ungi, I Bogáts, G Mansour, S Noiseux, N Sabaté, M Pomar, J Hickey, M Gershlick, A Buszman, P Bochenek, A Schampaert, E Pagé, P Dressler, O Kosmidou, I Mehran, R Pocock, SJ Kappetein, AP Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title | Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title_full | Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title_fullStr | Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title_full_unstemmed | Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title_short | Everolimus-eluting stents or bypass surgery for left main coronary artery disease. |
| title_sort | everolimus eluting stents or bypass surgery for left main coronary artery disease |
| work_keys_str_mv | AT stonegw everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT sabikjf everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT serruyspw everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT simontonca everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT genereuxp everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT puskasj everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT kandzaride everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT moricemc everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT lembon everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT brownwm everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT taggartdp everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT banninga everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT merkelyb everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT horkayf everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT boonstrapw everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT vanbovenaj everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT ungii everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT bogatsg everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT mansours everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT noiseuxn everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT sabatem everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT pomarj everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT hickeym everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT gershlicka everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT buszmanp everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT bocheneka everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT schampaerte everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT pagep everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT dresslero everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT kosmidoui everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT mehranr everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT pococksj everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease AT kappeteinap everolimuselutingstentsorbypasssurgeryforleftmaincoronaryarterydisease |